Life Sciences Patent Litigation Checklist: Listing, Notice Letters, Stays, Exclusivity, and Launch Risk

By Casey Scott McKay · 2024-08-02

This checklist runs a regulatory patent matter for either side, from the listing decision to judgment or settlement, on the statutory timetable that drives every other choice. It opens with the listing and use code audit that determines what an applicant must certify around and what an innovator can safely assert, then the unlisted patent search the Orange Book will never reveal. It specifies the notice letter that frames the dispute for three years, the forty-five-day decision that either buys or forfeits the thirty-month stay, and the schedule built backwards from that stay because it expires by operation of time. It covers discovery when the accused product is an application, the objective indicia file that decides obviousness, the marketing review programme a skinny label requires, the biologics exchange as a negotiation, and the at-risk launch model that belongs in front of a board before the stay lapses.

IP and Technology > Patent Litigation | Checklist | Published 2 August 2024 - Updated 29 October 2025 | Casey Scott McKay - marksy.us

Summary. This checklist runs a regulatory patent matter for either side, from the listing decision to judgment or settlement, on the statutory timetable that drives every other choice. It opens with the listing and use code audit that determines what an applicant must certify around and what an innovator can safely assert, then the unlisted patent search the Orange Book will never reveal. It specifies the notice letter that frames the dispute for three years, the forty-five-day decision that either buys or forfeits the thirty-month stay, and the schedule built backwards from that stay because it expires by operation of time. It covers discovery when the accused product is an application, the objective indicia file that decides obviousness, the marketing review programme a skinny label requires, the biologics exchange as a negotiation, and the at-risk launch model that belongs in front of a board before the stay lapses.

Keywords: listing audit · use code review · unlisted patent search · certification strategy · notice letter drafting · forty five day diary · selective assertion · backward schedule · cooperation lever · application discovery · validity focus · objective indicia file · skinny label policing · marketing review programme · biologics exchange decision · exclusivity mapping · at risk launch model · preliminary injunction readiness · settlement structuring · antitrust review

How to use this checklist

| Phase | What it covers | |---|---| | 1 | The listing audit | | 2 | Use code review | | 3 | The unlisted patent search | | 4 | Exclusivity mapping | | 5 | Certification strategy | | 6 | The notice letter | | 7 | The forty-five-day decision | | 8 | Selective assertion | | 9 | The backward schedule | | 10 | Application discovery | | 11 | Validity preparation | | 12 | The objective indicia file | | 13 | Bench trial preparation | | 14 | Skinny label policing | | 15 | The marketing review programme | | 16 | The biologics exchange | | 17 | At-risk launch modelling | | 18 | Preliminary injunction readiness | | 19 | Settlement structuring | | 20 | Antitrust review | | 21 | Parallel post-grant proceedings | | 22 | The launch risk memorandum |

Boxes marked [Gate] must clear before a certification is filed, a complaint is filed, or a launch decision is taken.

The matter. An innovator received a paragraph IV notice against three listed patents, asserted two, compressed the schedule at the scheduling conference by showing the arithmetic, and settled at month nineteen for entry three years before expiration with no payment.

Phase 1. The listing audit

[ ] [Gate] Confirm each listed patent is properly listable — claiming the drug substance, the drug product, or an approved method of use.
[ ] Exclude process patents, which the statute does not permit to be listed.
[ ] Flag device and packaging components, which sit at a contested boundary.
[ ] [Gate] Write a good-faith listing memo at the time each listing is made, recording the basis.
- Why. It is the answer to both a delisting counterclaim and an antitrust theory premised on listings that could not have been made in good faith.
[ ] As an applicant, audit the listings before certifying. An improperly listed patent is a target, and challenging it may open a carve-out route that avoids paragraph IV litigation entirely.
[ ] Reference: 21 U.S.C. § 355(b).

Phase 2. Use code review

[ ] [Gate] Compare each method-of-use listing's narrative use code against the patent claims.
[ ] Flag any use code broader than the claims.
- Why. An overbroad use code blocks a section viii carve-out that should have been available, and Caraco Pharmaceutical Laboratories v. Novo Nordisk permits a counterclaim to compel correction.
[ ] As an innovator, draft use codes to the claims rather than to the indication as marketed.
[ ] As an applicant, treat an overbroad use code as a target rather than an obstacle.
[ ] Re-check use codes whenever a supplement is approved, since new indications generate new listings.

Phase 3. The unlisted patent search

[ ] [Gate] Run a freedom-to-operate search independent of the Orange Book.
- Why. Process patents, later-issued patents, and patents on intermediates will never appear there and can be asserted after launch with no stay and no artificial act of infringement.
[ ] Search the innovator's portfolio, not only the listings.
[ ] Search third-party portfolios, since a patent held by neither party can still block entry.
[ ] Chart the significant hits against the proposed product. See Running a Freedom-to-Operate Analysis.
[ ] Record the search scope and date, because the opinion's value depends on both.

Phase 4. Exclusivity mapping

[ ] [Gate] Map the exclusivities on the same sheet as the patents.
- Why. An entry date is the later of the last patent's expiration and the last exclusivity's expiration, and a patent-only analysis produces a date wrong in the applicant's favour.
[ ] New chemical entity exclusivity, which bars submission and therefore delays the whole sequence.
[ ] New clinical investigation exclusivity, which bars approval for the studied change only.
[ ] Orphan drug exclusivity, attaching to an indication rather than a product and most often overlooked.
[ ] Pediatric exclusivity, an add-on extending existing patent and exclusivity periods, granted late and therefore capable of invalidating an earlier launch model.
[ ] First-applicant exclusivity, with its forfeiture events.
[ ] Biologics exclusivity — twelve years from first licensure, four before submission.
[ ] Identify which one actually controls the entry date.

Phase 5. Certification strategy

[ ] Paragraph III for patents to be waited out; approval deferred, no litigation.
[ ] Paragraph IV where invalidity, unenforceability, or non-infringement is genuinely arguable.
[ ] Section viii where a method-of-use patent can be carved around, subject to the Phase 2 use code check.
[ ] Mixed certifications are normal across a single application.
[ ] [Gate] Confirm the first-to-file position, since exclusivity is frequently the whole economic case for the programme.
[ ] Screen forfeiture exposure — failure to market, failure to obtain tentative approval within thirty months, amendment of the certification, and an agreement violating antitrust law.
[ ] Reference: 21 U.S.C. § 355(j).

Phase 6. The notice letter

[ ] [Gate] Have trial counsel draft it, reviewed by regulatory counsel — not the reverse.
- Why. It frames the dispute, will be quoted back for three years, and is read closely for admissions.
[ ] Include a detailed statement of the factual and legal basis, patent by patent, claim by claim.
[ ] For non-infringement: the claim limitations at issue and why the proposed product does not meet them, described in the patent's own words rather than paraphrased.
- Trap. A paraphrase is a claim construction position.
[ ] For invalidity: the prior art identified precisely with dates, and the theory — anticipation under 35 U.S.C. § 102, obviousness under 35 U.S.C. § 103, or a failure under 35 U.S.C. § 112.
[ ] Offer confidential access to the application on stated, negotiable terms.
[ ] [Gate] Include nothing else — no commercial plans, no market characterizations, no statements of intention beyond the statute's requirement.
[ ] Check consistency with the application, since any divergence is a discovery target.

Phase 7. The forty-five-day decision

[ ] [Gate] Diary forty-five days from receipt, not from the letter's date.
- Trap. Route incoming notice letters to a named recipient with a same-day acknowledgment protocol.
[ ] Understand the consequence. Suing attaches the automatic thirty-month stay, running from receipt of the notice. Declining forfeits it, and the applicant may seek declaratory relief under 28 U.S.C. § 2201.
[ ] Confirm standing and ownership across the asserted patents.
[ ] Check the term position, including extension under 35 U.S.C. § 156 and double patenting exposure. See the Patent Term Checklist.
[ ] Choose venue under 28 U.S.C. § 1400.
[ ] Plead the artificial act of infringement under 35 U.S.C. § 271(e)(2).

Phase 8. Selective assertion

[ ] [Gate] Do not assert every listed patent by default.
- Why. Every patent asserted is a patent whose validity is put at risk, and a weak patent asserted alongside a strong one dilutes the case.
[ ] Assess each patent's validity exposure before including it.
[ ] Leave contested listings unasserted where asserting invites a delisting counterclaim and an antitrust theory.
[ ] Consider whether to delist a patent that should not have been listed, going forward.
[ ] Record the assertion decision and its reasoning.

Phase 9. The backward schedule

[ ] [Gate] Do the arithmetic before the scheduling conference. Judgment before month thirty; trial three to six months earlier; expert discovery before trial preparation; claim construction before expert reports; fact discovery before expert reports.
[ ] Compare against the district's normal pace, which frequently does not fit.
[ ] Present the arithmetic to the court rather than asserting urgency.
[ ] Use the cooperation lever. A court may shorten or extend the stay for failure to cooperate reasonably in expediting the action — and both sides forget this.
[ ] Push claim construction early, since the ruling determines settlement value and informs the at-risk launch decision.
[ ] Raise consolidation with parallel applicants at the conference.
[ ] Track tentative approval, since failure within thirty months forfeits first-applicant exclusivity and changes leverage.

Phase 10. Application discovery

[ ] [Gate] The accused product is the application. No reverse engineering, no test purchase, no sales data.
[ ] As innovator, obtain the application early and completely, and confirm the commercial product will match it.
[ ] Watch for later amendments to the applicant's specification, which can change the infringement analysis.
[ ] As applicant, negotiate confidentiality hard, since manufacturing details, batch records, and analytical methods all enter the case.
[ ] Expect no damages discovery absent an at-risk launch, which removes the damages expert battle entirely.
[ ] Coordinate with parallel defendants, typically with a lead defendant carrying the merits.

Phase 11. Validity preparation

[ ] Expect validity to decide the case, because infringement is usually straightforward where the applicant is copying the approved product.
[ ] Assemble the prior art, which here includes published applications, clinical trial disclosures, regulatory submissions, and literature — much of it the innovator's own.
[ ] Focus on obviousness under 35 U.S.C. § 103, and specifically on reasonable expectation of success.
[ ] Prepare written description and enablement under 35 U.S.C. § 112 for genus and formulation claims.
[ ] [Gate] Audit the candor position. These portfolios have unusually high exposure because the innovator generated much of the art. See the Duty of Candor Checklist.

Phase 12. The objective indicia file

[ ] [Gate] Build it from the outset of development, not at expert report stage.
- Why. Indicia assembled after a notice letter arrives read as advocacy, because they are.
[ ] Unexpected results, compared against the closest prior art, with contemporaneous records showing surprise.
[ ] Long-felt unmet need — literature, conference proceedings, and the company's own failed programmes, which are the evidence most likely to have been discarded.
[ ] Failure of others — published failures, abandoned programmes, competitor patents on approaches that did not work.
[ ] Commercial success with a documented nexus to the claimed feature rather than to price, marketing, or an unclaimed feature.
[ ] Skepticism of experts, from contemporaneous statements.
[ ] Licensing and industry praise.
[ ] Do not overreach on copying, which is weak here because the applicant copies by design.

Phase 13. Bench trial preparation

[ ] Expect no jury right absent a damages claim, which changes presentation and expert use.
[ ] Prepare a technology tutorial rather than a lay-comprehension opening.
[ ] Select experts for validity — formulation, medicinal chemistry, clinical — and expect damages experts to be unnecessary.
[ ] Build the case around the intrinsic record and the prior art, not around demonstratives.
[ ] Anticipate the remedy. On a finding of infringement, an order under 35 U.S.C. § 271(e)(4) setting the approval date no earlier than patent expiry, plus injunctive relief and damages if a launch occurred.

Phase 14. Skinny label policing

[ ] [Gate] Understand that carving the indication out of the label is necessary and not sufficient.
- Why. GlaxoSmithKline v. Teva Pharmaceuticals sustained an inducement verdict under 35 U.S.C. § 271(b) on marketing evidence, and Amarin Pharma v. Hikma Pharmaceuticals allowed a claim past the pleadings on similar theories.
[ ] Identify the phrases that create the case: unqualified therapeutic equivalence claims; references to the carved-out indication; general substitutability statements; unqualified AB-rating claims.
[ ] Include third-party descriptions the company supplied and did not correct.
[ ] As innovator, collect the applicant's marketing contemporaneously — press releases, conference materials, field collateral, formulary submissions. The evidence is public and ephemeral.

Phase 15. The marketing review programme

[ ] [Gate] Scope it to every communication about the product, to anyone, for the life of the carve-out.
[ ] Cover press releases, sales training and scripts, detail aids, formulary dossiers, website copy, conference materials, investor presentations, medical information responses, and distributor communications.
[ ] Name a single reviewer with a defined turnaround.
[ ] Use pre-approved language blocks plus spot auditing where volume makes individual review impractical, and record the audit results.
[ ] Train the sales force specifically on the carve-out, and document the training.
[ ] Monitor third-party databases and formulary listings, and seek correction of inaccurate descriptions.
[ ] Diary the end date, since programmes like this outlive the people who set them up.

Phase 16. The biologics exchange

[ ] [Gate] Decide whether to participate, since Sandoz v. Amgen held the exchange under 42 U.S.C. § 262(l) is not enforceable by federal injunction.
[ ] Weigh the manufacturing disclosure, which for a biologic is substantially the product.
[ ] Negotiate confidentiality terms hard at step one.
[ ] As sponsor, value the disclosure — it is frequently the only route to assessing process patent infringement.
[ ] Work the sequence: application and process information; sponsor's patent list; applicant's detailed contentions; sponsor's reply; negotiation over the immediate-litigation list; exchange mechanism if no agreement; suit within thirty days.
[ ] Handle the notice of commercial marketing — one hundred and eighty days before first marketing, and it may be given before licensure.
[ ] Note there is no automatic stay and no equivalent first-applicant exclusivity.

Phase 17. At-risk launch modelling

[ ] [Gate] State the window as a date range — from stay expiry to expected judgment.
[ ] Model exposure against the innovator's margins and volumes, not the applicant's revenue.
- Trap. A modest generic revenue line corresponds to an enormous damages figure.
[ ] Add enhanced damages exposure under 35 U.S.C. § 284 where an adverse ruling precedes launch.
[ ] Assess the merits honestly, ideally after a claim construction ruling.
[ ] Confirm the exclusivity position and whether an authorized generic is ready.
[ ] [Gate] Test balance sheet capacity. The judgment must be survivable; this is the constraint that usually controls and it is a board question.
[ ] As innovator, assess collectibility where the applicant's parent is offshore.

Phase 18. Preliminary injunction readiness

[ ] Prepare the papers before the stay expires, not when launch is announced.
[ ] Build the irreparable harm record — brand pricing does not recover after generic entry, which makes the harm concrete and largely irreversible.
[ ] Anticipate the validity challenge at the preliminary stage.
[ ] Consider an authorized generic launched simultaneously, which compresses the applicant's exclusivity value.
[ ] As applicant, assume the motion within days of any launch and plan the response in advance.

Phase 19. Settlement structuring

[ ] [Gate] Bring antitrust counsel into the design, not the review.
[ ] Understand what draws scrutiny: payments large relative to expected litigation costs; payments unexplained by any service; entry dates close to patent expiry; agreements not to launch an authorized generic, treated as compensation in kind.
[ ] Prefer defensible structures: meaningful early entry with no payment; a licence with a running royalty; payments documented at the time as tied to identifiable services or genuine cost avoidance.
[ ] Model the entry date against the exclusivity map from Phase 4, since settling to a date after a controlling exclusivity expires gives away nothing.
[ ] Comply with reporting obligations, which apply as a matter of course.

Phase 20. Antitrust review

[ ] Apply the rule of reason under FTC v. Actavis and 15 U.S.C. § 1. Neither presumptively lawful nor presumptively unlawful.
[ ] Document the litigation cost estimate contemporaneously, since it is the benchmark against which a payment's size is assessed.
[ ] Review the listing practice for exposure premised on listings that could not have been made in good faith.
[ ] Review any exclusivity-parking allegation against the forfeiture provisions.
[ ] Keep the settlement file clean, on the assumption that it will be produced.

Phase 21. Parallel post-grant proceedings

[ ] Decide whether to file under 35 U.S.C. § 311, weighing cost, estoppel, and the different standard.
[ ] Model the timetable interaction with the thirty-month stay.
[ ] Assess stay exposure in the district court case.
[ ] Plan for inconsistent outcomes, which are possible given different standards and records.
[ ] Raise it at the scheduling conference rather than after institution. See the PTAB Practice Toolkit.

Phase 22. The launch risk memorandum

[ ] Section one: the patents in the way, listed and unlisted, with expirations including any extension.
[ ] Section two: certification strategy per patent.
[ ] Section three: the merits, with candid probabilities.
[ ] Section four: the exclusivity position and what it is worth at realistic pricing.
[ ] Section five: the timetable, with the at-risk window as a date range.
[ ] Section six: at-risk exposure, against brand margins.
[ ] Section seven: inducement exposure where a skinny label is used.
[ ] Section eight: the settlement range with antitrust constraints noted.
[ ] Section nine: the decision, named and dated, with trigger conditions.
[ ] [Gate] Assemble it as one document. The inputs sit with regulatory affairs, litigation counsel, commercial, and finance, and the decisions that go wrong are made with one section missing.

Outcome. The listing audit found the third listed patent, covering a device component, at the boundary of what is listable; it was left unasserted and later delisted, removing both a delisting counterclaim and an antitrust theory from the case. Suit was filed on two patents within the forty-five days and the thirty-month stay attached. At the scheduling conference the innovator produced the backward arithmetic — judgment by month twenty-eight, trial by month twenty-three, claim construction by month fourteen — against a district pace that would have put trial at month thirty-four, and the court compressed. Discovery focused on the application and on validity; the applicant's manufacturing specifications did not match the excipient characterization in its notice letter, which became the infringement case. Claim construction at month fourteen split, and both sides re-modelled. With exclusivity intact and tentative approval obtained, the applicant's leverage was at its maximum, and the case settled at month nineteen for entry three years before the composition patent's expiration, with no payment and no restriction on an authorized generic — a structure chosen partly because it required no explanation to anyone.

Phase 23. The timetable, as a working calendar

Print this and put it on the wall. Every decision in the matter hangs off one of these dates.

| Date | Event | Decision it forces | |---|---|---| | Day 0 | Abbreviated application submitted with a paragraph IV certification | The submission is itself the act of infringement under 35 U.S.C. § 271(e)(2) | | Within 20 days | Notice letter sent | Applicant: what the letter concedes. Innovator: read it twice | | Receipt | Forty-five-day clock starts | Route to a named recipient; diary the same day | | Day 45 | Suit or no suit | Sue and get the stay; decline and the applicant may be approved when the agency is ready | | Months 1-30 | The stay period, running from receipt of notice | The entire litigation window; it does not extend because discovery is slow | | ~Month 14 | Claim construction ruling, if the schedule was built properly | Both sides re-model; the applicant's at-risk analysis becomes real | | ~Month 24 | Tentative approval deadline for first-applicant exclusivity | Failure forfeits exclusivity and shifts settlement leverage | | Month 30 | Stay lapses by operation of time | If unresolved, the applicant may launch at risk | | On launch | Damages exposure crystallizes | Lost profits against brand margins; preliminary injunction within days | | On judgment | Order under 35 U.S.C. § 271(e)(4) | Approval date set no earlier than patent expiry |

[ ] [Gate] Build the litigation plan backwards from month thirty, not forwards from filing.
[ ] Mark the gap between expected judgment and stay expiry. That gap is the at-risk launch window.
[ ] Diary the tentative approval date independently, since it moves leverage without anything happening in court.

Phase 24. Evidence request, written in advance

Draft once so it can be issued unchanged when the matter opens.

[ ] The abbreviated application, complete, including all amendments and supplements.
[ ] Manufacturing specifications, batch records, and analytical methods for the proposed product.
[ ] The notice letter and all correspondence with the agency about the certification.
[ ] Bioequivalence data and the studies supporting it.
[ ] Every listing decision memorandum for the asserted patents, with the good-faith basis recorded.
[ ] Use code narratives as submitted and as amended, with dates.
[ ] Prior art in the innovator's possession — including its own publications, clinical trial disclosures, and regulatory submissions.
[ ] The objective indicia file — laboratory records showing surprise, failed programme records, literature on long-felt need, and nexus evidence for commercial success.
[ ] All marketing and promotional material for a carved-out product, including field collateral, formulary submissions, and third-party database entries.
[ ] Sales force training materials and records for a carve-out.
[ ] Exclusivity determinations and any correspondence about forfeiture.
[ ] Patent term extension application and grant, with the regulatory review period calculation.
[ ] Prosecution histories for every asserted patent, with the candor position mapped.

Why this belongs here. The objective indicia file and the marketing records rarely exist in retrievable form, and both are assembled far more cheaply during development and launch than during discovery — where the other side will find what remains regardless.

Phase 25. Party-type boxes

Run the base checklist, then the boxes for your client.

Innovator with a single approved product.

[ ] The product's revenue profile changes on a date certain if the case is lost; that is a business forecasting input, not a legal cost.
[ ] Confirm the extension election under 35 U.S.C. § 156 sits on the patent whose extended life is most commercially useful.
[ ] Audit the candor position across the family before asserting, since the prior art is largely the innovator's own.
[ ] Prepare the preliminary injunction papers before month thirty, not when launch is announced.

Innovator with a broad portfolio.

[ ] Assertion decisions are portfolio decisions; a patent invalidated here is invalidated everywhere.
[ ] Map double patenting exposure across the family before asserting adjacent patents. See the Patent Term Checklist.
[ ] Coordinate parallel cases against multiple applicants, with consistent claim construction positions across all of them.

First-filer generic.

[ ] Exclusivity is the economic case; protect it by tracking every forfeiture event.
[ ] Tentative approval within thirty months is a hard requirement, not an aspiration.
[ ] Model the shared-exclusivity scenario where same-day filers exist.
[ ] Assume an authorized generic will launch into the exclusivity period and price accordingly.

Subsequent-filer generic.

[ ] Approval is blocked during the first filer's exclusivity regardless of the merits, so the litigation timetable and the entry date can diverge substantially.
[ ] Watch the first filer's forfeiture events, which may accelerate entry without any action by this client.
[ ] Settlement leverage is lower; price accordingly.

Section viii applicant.

[ ] The marketing review programme in Phase 15 is the principal operational cost and it is never budgeted.
[ ] Challenge an overbroad use code early under Caraco Pharmaceutical v. Novo Nordisk rather than accepting a carve-out that is narrower than the claims require.
[ ] Track third-party descriptions of the product, since they become the innovator's evidence.

Biosimilar applicant or reference sponsor.

[ ] Decide about participation in the exchange deliberately; Sandoz v. Amgen makes it optional.
[ ] There is no automatic stay, so the leverage structure is entirely different.
[ ] The manufacturing disclosure is the central commercial decision, not a procedural step.
[ ] Twelve-year exclusivity may control the entry date regardless of the patents.

Phase 26. The notice letter, section by section

The applicant's most consequential document, and the structure that satisfies the statute without giving anything away.

[ ] 1. Identification. The applicant, the application, the reference product, and the listed patents certified against. Precise and short.
[ ] 2. Statement of certification. That the applicant has certified under paragraph IV that each identified patent is invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of the proposed product.
[ ] 3. Offer of confidential access to the application, on stated terms — negotiable, and worth negotiating.
[ ] 4. Per patent, the detailed statement.
- Non-infringement: the claim limitations at issue and why the proposed product does not meet them, with reference to the application's specifications.
- Invalidity: the prior art relied on with dates and specific disclosures, and the theory under 35 U.S.C. § 102, 35 U.S.C. § 103, or 35 U.S.C. § 112.
[ ] 5. Nothing else. No commercial plans, no market characterizations, no statements of intention beyond the statutory requirement.
[ ] [Gate] Address every claim limitation once, accurately. A limitation glossed over is the limitation the innovator will focus on.
[ ] [Gate] Describe limitations in the patent's own words. A paraphrase is a claim construction position and it will be quoted back.
[ ] Identify prior art precisely, since a vague reference invites a motion attacking the sufficiency of the notice.
[ ] Check consistency against the application, because any divergence between what the letter says the product is and what the application says it is becomes the infringement case.

Phase 27. Ninety-day opening

For the innovator, from receipt of a notice letter.

[ ] Days 1-3. Log receipt, diary forty-five days, distribute to trial counsel. Read the letter twice — once for theories, once for admissions.
[ ] Days 3-10. Listing audit and use code review on the asserted patents. Locate the good-faith listing memoranda.
[ ] Days 5-15. Standing and ownership confirmation. Term position, including extension and double patenting exposure.
[ ] Days 10-25. Selective assertion analysis — which patents, and which to leave out.
[ ] Days 20-40. Venue selection and complaint drafting, pleading the artificial act of infringement under 35 U.S.C. § 271(e)(2).
[ ] Day 45. File.
[ ] Days 45-60. Backward schedule prepared with the arithmetic written out. Consolidation position determined for parallel applicants.
[ ] Days 60-75. Scheduling conference; present the arithmetic; raise the cooperation provision if compression is resisted.
[ ] Days 60-90. Application discovery served. Objective indicia file assembled from development records. Candor audit run across the asserted patents.

For the applicant, the mirror sequence runs from submission: notice letter drafted by trial counsel and sent within twenty days; confidential access terms negotiated; the launch risk memorandum begun immediately rather than at month twenty-eight; and the marketing review programme stood up before any carve-out product is promoted.

Phase 28. Five things to say at the outset

[ ] To the innovator's board, on receipt of a notice letter. "We have forty-five days to decide whether to sue. Suing buys thirty months during which they cannot be approved. Not suing means they can be approved as soon as the agency is ready. The thirty months is not extendable by agreement and it does not care how the case is going."
[ ] To the applicant's board, on filing. "Nothing prevents them approving us after month thirty. If the case is not decided by then we can launch, and if we lose afterwards the damages are measured against their margins, not our revenue. That number has to be survivable before we plan around launching."
[ ] To regulatory affairs, on both sides. "Listing decisions and use codes are litigation decisions. An overbroad use code blocks a carve-out that should be available and invites a correction counterclaim. An improperly listed patent invites a delisting counterclaim and an antitrust theory. Write the good-faith memo when the listing is made."
[ ] To marketing, where a skinny label is used. "The label is the easy part. Every statement anyone makes about this product, anywhere, for the life of the carved-out patent, is potential inducement evidence — and the case will be built from your materials rather than from the label."
[ ] To the deal team, before settlement structuring. "The structures that look best commercially are the ones a competition authority reads most closely. Bring antitrust counsel into the design, not the review."

Why these five. Each moves a decision from the department that would otherwise make it in isolation to the person who can see the whole timetable. That is the entire management task in this practice; the doctrine is comparatively easy by comparison.

Phase 29. What differs from ordinary patent litigation

Worth restating for anyone arriving from general practice, because the instincts do not transfer.

[ ] No accused product exists. Infringement is assessed against the application, produced in discovery. There is no reverse engineering and no test purchase.
[ ] The complaint is filed against a deadline, not against readiness. Forty-five days, whatever the state of the investigation.
[ ] Damages are usually irrelevant absent an at-risk launch, so the remedy is an approval-date order under 35 U.S.C. § 271(e)(4).
[ ] Bench trials are the norm, since without a damages claim there is frequently no jury right.
[ ] Validity is the main event, because the applicant is copying by design.
[ ] The prior art is largely the innovator's own — published applications, clinical disclosures, regulatory submissions — which is why the candor exposure is unusually high.
[ ] Multiple defendants are coordinated, with a lead carrying the merits.
[ ] A parallel post-grant proceeding may run on a different timetable with a different standard.
[ ] The settlement is read by a competition authority, which is true in almost no other patent context.

Key Authorities at a Glance

| Authority | Proposition | |---|---| | 35 U.S.C. § 271(e)(1) | Research safe harbor | | 35 U.S.C. § 271(e)(2) | Artificial act of infringement | | 35 U.S.C. § 271(e)(4) | Approval date orders | | 35 U.S.C. § 271(b) | Induced infringement | | 35 U.S.C. § 156 | Patent term extension | | 35 U.S.C. § 112 | Written description and enablement | | 35 U.S.C. § 103 | Obviousness and objective indicia | | 35 U.S.C. § 102 | Anticipation | | 35 U.S.C. § 284 | Damages and enhancement | | 35 U.S.C. § 285 | Fee shifting | | 35 U.S.C. § 311 | Post-grant challenge | | 21 U.S.C. § 355(j) | Abbreviated application and certifications | | 21 U.S.C. § 355(b) | Listing obligations | | 42 U.S.C. § 262(l) | Biologics information exchange | | 42 U.S.C. § 262(k) | Biosimilar pathway | | 28 U.S.C. § 2201 | Declaratory judgment | | 28 U.S.C. § 1400 | Patent venue | | Merck KGaA v. Integra Lifesciences | Breadth of the safe harbor | | Eli Lilly v. Medtronic | Safe harbor and devices | | Caraco Pharmaceutical v. Novo Nordisk | Use code correction | | GlaxoSmithKline v. Teva Pharmaceuticals | Skinny label inducement | | Amarin Pharma v. Hikma Pharmaceuticals | Inducement pleading | | Sandoz v. Amgen | Exchange not federally enjoinable | | FTC v. Actavis | Reverse payments | | Warner-Lambert v. Apotex | Off-label use | | 15 U.S.C. § 1 | Settlement antitrust exposure |

The five things people get wrong

Letting regulatory counsel draft the notice letter. It is a litigation document that happens to be filed with a regulator, it frames the dispute for three years, and it is read closely for admissions. Trial counsel writes it; regulatory counsel reviews it.

Agreeing a schedule that cannot reach judgment before month thirty. The stay expires by operation of time regardless of the case's progress, so a schedule running past it concedes the applicant's ability to launch at risk without any ruling. Do the arithmetic before the scheduling conference and show it to the court.

Asserting every listed patent. Each one asserted is a patent whose validity is put at risk, and a contested listing asserted alongside strong patents invites a delisting counterclaim and an antitrust theory into a case that did not need them.

Treating the carved-out label as the whole compliance answer. After GlaxoSmithKline v. Teva Pharmaceuticals, the inducement case is built from marketing conduct rather than from the label, and the review programme runs for the life of the carve-out.

Modelling at-risk exposure against generic revenue. Damages are lost profits measured against the innovator's margins and volumes, so a modest revenue line corresponds to an enormous figure — and the survivability question belongs in front of a board before the stay lapses, not at the moment it does.